Possibilities of imaging of urogenital tract tumors by ¹⁸FDG-PET/CT

Czech version

Authors: doc. MUDr. Jiří Ferda, Ph.D. ^1,2; MUDr. Eva Ferdová ^1,2; prim. MUDr. Jan Záhlava ¹; doc. MUDr. Milan Hora, Ph.D. ³; MUDr. Miroslava Schützová ⁴
Authors‘ workplace: oddělení nukleární medicíny FN Plzeň-Lochotín ¹; Radiodiagnostická klinika LF UK a FN Plzeň ²; Urologická klinika LF UK a FN Plzeň ³; Hematoonkologické oddělení FN Plzeň ⁴
Published in: Urol List 2006; 4(2): 36-40

Overview

The hybrid imaging system PET/CE, which has been developed at the beginning of this decade, provides the possibility of a fusion of anatomical visualization by means of computer tomography and visualization of the metabolic activity of a carrier labeled with a radionuclide with decay (most often ¹⁸F isotope with a half-life of 110 minutes). The subsystem of computer tomography serves not only for simple CT-examination but is also used in a reconstruction algorithm of PET data for so-called attenuation correction, i.e. correction for the attenuation of activity of deep-seated structures caused by absorption of the radiation in tissues. The authors describe the use of ¹⁸FDG-PET/CT for detection of tumors of the urinary tract outlet system, testicles, prostate and hemato-oncological tumors, and assess the suitability and benefits of this examination mode in these indications. With a correct indication for ¹⁸FDG-PET/CT examination, this modality brings, despite the high costs, a considerable medical profit as well as economical saving of oncological therapy costs.

KEY WORDS:
renal tumors, urinary tract outlet system, prostate, hemato-oncological tumors, positron emission tomography, computer tomography

Sources

1. Bar Shalom R, Keidar Z, Guralnik L et al. Added value of fused PET/CT imaging with FDG in diagnostic imaging and management of cancer patients. J Nucl Med 2002; 43: 32-33.

2. Antoch G, Vogt FM, Freudenberg LS et al. Whole body dual modality PET/CT and whole body MRI for tumor staging in oncology. JAMA 2003; 290: 3199-3206.

3. Kocher F, Grimmel S, Hautmann R et al. Positron emission tomography. Introduction of a new procedure in diagnosis of urologic tumors and initial clinical results. J Nucl Med 1994; 35: 223.

4. Bachor R, Kotzerke J, Gottfried HW et al. Positron emission tomography in diagnosis of renal cell carcinoma. Urologe A 1996; 35: 146-150.

5. Safaei A, Figlin R, Hoh CK et al. The usefulness of F-18 deoxyglucose whole body positron emission tomography (PET) for restaging of renal cell carcinoma. Clin Nephrol 2002; 57: 56-62.

6. Choyke PL, Amis ES jr, Bigongiari LR et al. Renal cell carcinoma staging. American College of Radiology. ACR Appropriateness Criteria. Radiology 2000; 215(Suppl):721-725.

7. Israel G, Bosniak MA. Renal imaging for diagnosis and staging of renal cell carcinoma. Urol Clin N Am 2003; 30: 499-514.

8. Raptopoulos VD, Blake SP, Weisinger K et al. Multiphase contrast-enhanced helical CT of liver metastases from renal cell carcinoma. Eur Radiol 2001; 11: 2504-2509.

9. Kopka L, Fischer U, Zoller G et al. Dual-phase helical CT of the kidney: value of corticomedullary and nephrographic phase for evaluation of renal lesions and preoperative staging of renal cell carcinoma. AJR 1997; 169: 1573-1578.

10. Cheon JJWY, Wafgenr BJ, Davis CJ. AFIP archives: transitional cell carcinoma of the urinary tract: radiologic-pathologic correlation. Radiographics 1998; 18: 123-128.

11. Cremerius U, Effert PJ, Adam G et al. FDG PET for detection and therapy control of metastatic germ cell tumor. J Nucl Med 1998; 39: 815-822.

12. Cremerius U, Widberger H, Borchers H et al. Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer? - Results of a study in 50 patients. Urolology 1999; 54: 900-904.

13. Liu IJ, Zafar MB, Lai YH et al. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinical organ-confined prostate cancer. Urology 2001; 57: 108-111.

14. Kosuda S, Kison PV, Greenough R et al. Preliminary assessment of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with bladder cancer. Eur J Nucl Med 1997; 24: 615-620.

15. Freudenberg LS, Antoch G, Schutt P et al. FDG-PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging 2003; 26: 256-198.